Consequently, some DLBCLs accumulate somatic mutations in the IRF4 binding region of BCL6, thereby causing high expression of BCL6 to be maintained in the face
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor
mTORC1 inhibitor
Consequently, some DLBCLs accumulate somatic mutations in the IRF4 binding region of BCL6, thereby causing high expression of BCL6 to be maintained in the face